| Cellular imaging predictions of clinical drug-induced liver injury JJ Xu, PV Henstock, MC Dunn, AR Smith, JR Chabot, D de Graaf Toxicological sciences 105 (1), 97-105, 2008 | 515 | 2008 |
| A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects S Talukdar, Y Zhou, D Li, M Rossulek, J Dong, V Somayaji, Y Weng, ... Cell metabolism 23 (3), 427-440, 2016 | 478 | 2016 |
| Probing polymerization forces by using actin-propelled lipid vesicles A Upadhyaya, JR Chabot, A Andreeva, A Samadani, A van Oudenaarden Proceedings of the National Academy of Sciences 100 (8), 4521-4526, 2003 | 233 | 2003 |
| Increasing serum half-life and extending cholesterol lowering in vivo by engineering an antibody with pH-sensitive binding to PCSK9 J Chaparro-Riggers, H Liang, RM DeVay, L Bai, JE Sutton, W Chen, ... Journal of Biological Chemistry, 2012 | 216 | 2012 |
| Stochastic gene expression out-of-steady-state in the cyanobacterial circadian clock JR Chabot, JM Pedraza, P Luitel, A Van Oudenaarden Nature 450 (7173), 1249-1252, 2007 | 167 | 2007 |
| Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese … AM Kim, VR Somayaji, JQ Dong, TP Rolph, Y Weng, JR Chabot, ... Diabetes, Obesity and Metabolism 19 (12), 1762-1772, 2017 | 138 | 2017 |
| Anti-PCSK9 antibodies with pH dependent antigen binding J Pons, JR Chabot, JFC Riggers, BC Gomes, H Liang, K Mayawala, ... US Patent 9,029,515, 2015 | 131 | 2015 |
| Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin … Y Weng, JR Chabot, B Bernardo, Q Yan, Y Zhu, MB Brenner, C Vage, ... PloS one 10 (3), e0119104, 2015 | 69 | 2015 |
| Social context of shell acquisition in Coenobita clypeatus hermit crabs RD Rotjan, JR Chabot, SM Lewis Behavioral Ecology 21 (3), 639-646, 2010 | 46 | 2010 |
| Apparatus and methods for aspirating and separating components of different densities from a physiological fluid containing cells NF Duffy, JR Chabot US Patent 9,272,083, 2016 | 45 | 2016 |
| Small molecule proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: hit to lead optimization of systemic agents AT Londregan, L Wei, J Xiao, NG Lintner, D Petersen, RG Dullea, ... Journal of medicinal chemistry 61 (13), 5704-5718, 2018 | 41 | 2018 |
| Liver‐Targeted Small‐Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis KF McClure, DW Piotrowski, D Petersen, L Wei, J Xiao, AT Londregan, ... Angewandte Chemie 129 (51), 16436-16440, 2017 | 40 | 2017 |
| Analysis of mechanistic pathway models in drug discovery: p38 pathway BS Hendriks, F Hua, JR Chabot Biotechnology progress 24 (1), 96-109, 2008 | 37 | 2008 |
| CELL SEPARATION METHOD AND APPARATUS N Duffy, JR Chabot, EH Kislauskis EP Patent 1,940,550, 2008 | 35* | 2008 |
| Assessing the feasibility of neutralizing osteopontin with various therapeutic antibody modalities V Farrokhi, JR Chabot, H Neubert, Z Yang Scientific reports 8 (1), 1-7, 2018 | 33 | 2018 |
| Two additive mechanisms impair the differentiation of'substrate-selective'p38 inhibitors from classical p38 inhibitors in vitro BS Hendriks, KM Seidl, JR Chabot BMC Systems Biology 4, 1-17, 2010 | 30 | 2010 |
| Glyco-engineered long acting FGF21 variant with optimal pharmaceutical and pharmacokinetic properties to enable weekly to twice monthly subcutaneous dosing Y Weng, T Ishino, A Sievers, S Talukdar, JR Chabot, A Tam, W Duan, ... Scientific Reports 8 (1), 4241, 2018 | 23 | 2018 |
| Cell concentration devices and methods that include an insert defining a lumen and a cannula assembly AH Levine, JC Meade, N Tischler, JR Chabot, A McGillicuddy, NF Duffy US Patent 10,603,665, 2020 | 15 | 2020 |
| Examination of the human cytochrome P4503A4 induction potential of PF-06282999, an irreversible myeloperoxidase inactivator: integration of preclinical, in silico, and … JQ Dong, JR Gosset, OA Fahmi, Z Lin, JR Chabot, SG Terra, V Le, ... Drug Metabolism and Disposition 45 (5), 501-511, 2017 | 15 | 2017 |
| Cell separation method and apparatus N Duffy, J Chabot, E Kislauskis US Patent App. 11/588,835, 2007 | 15 | 2007 |
Roberto A. CalleRegeneron PharmaceuticalsDirección de correo verificada de regeneron.com
